Coya Therapeutics, Inc.
Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing therapies intended to enhance regulatory T-cell (Treg) function for neurodegenerative, autoimmune and metabolic diseases. Its approaches include Treg-enhancing biologics, Treg-derived exosomes and autologous Treg cell therapy;… From the company’s description.
Over the twelve months to Jun 30, 2026, Coya Therapeutics, Inc. reported revenue of $8.02M, up 1791.3% from a year earlier, and a net loss of $21.67M. Its operating margin was −288.7%, and operations used $15.72M in cash. In fiscal 2025, it reported revenue of $7.95M, up 123.6% from fiscal 2024, and a net loss of $21.23M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Coya Therapeutics, Inc. does
In the company’s own words
Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing therapies intended to enhance regulatory T-cell (Treg) function for neurodegenerative, autoimmune and metabolic diseases. Its approaches include Treg-enhancing biologics, Treg-derived exosomes and autologous Treg cell therapy; it has no commercial products described. Its leading candidate, COYA 302, combines low-dose interleukin-2 (COYA 301) with CTLA4-Ig and is being studied in a Phase 2 trial for amyotrophic lateral sclerosis (ALS); the company is also planning clinical development for frontotemporal dementia. COYA 303 combines COYA 301 with a GLP-1 receptor agonist and remains in preclinical development. COYA 301 is also being developed as a potential standalone therapy and as the backbone for combination treatments. The company’s exosome programs include COYA 201, an allogeneic Treg-derived candidate in preclinical development. Coya has completed Phase 1 and Phase 2a studies of autologous Treg cell therapy in ALS. Its operations focus on research and development, funded primarily through securities sales.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- HOUSTON, TX
- Fiscal year end
- December
- CIK
- 1835022
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Coya Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Coya Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Coya Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Coya Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Coya Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Coya Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”